Browse Reports

Alaunos Therapeutics, Inc. is a preclinical-stage biopharmaceutical company focused on developing novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders such as MASLD. The company’s lead program, ALN1003, employs a differentiated non-hormonal, non-incretin mechanism distinct from hormone-based therapies like GLP-1 receptor agonists. Positive preclinical data from two diet-induced obesity mouse model studies demonstrated dose-dependent body weight loss, favorable body composition changes, reductions in liver weight, and improvements in liver function and metabolic biomarkers. The company previously focused on clinical-stage oncology cell therapy programs but discontinued these in August 2023 due to high costs and financing challenges. Alaunos has not generated product revenue and has incurred significant net losses since inception. It outsources manufacturing to third-party CDMOs and is engaged in chemistry, manufacturing, and controls activities to optimize formulations and scale production. Intellectual property protection efforts include pending patent applications and computational chemistry programs to develop analogs. The company faces risks related to capital needs, regulatory approval, competition, and Nasdaq listing compliance.

American Clean Resources Group, Inc. (ACRG) is an exploration stage company with administrative offices in Lakewood, Colorado, and owns property in Tonopah, Nevada. The company plans to construct a permitted custom processing toll milling facility on its Tonopah property, which will include an analytical laboratory, a pyrometallurgical plant, and a hydrometallurgical recovery plant. The toll milling process involves crushing and grinding mined material to facilitate extraction of precious metals such as gold, silver, and platinum group metals. The company also intends to offer chemical production outsourcing services for industrial clients lacking in-house expertise or permits. ACRG has not yet commenced revenue-generating operations and must obtain several permits before construction and operation can begin. The company owns significant land assets, including approximately 1,186 deeded acres with an estimated 2.2 million tons of historic tailings. The business plan and operations remain subject to significant uncertainties, including permit acquisition and financing.

Karman Holdings Inc. is a company engaged in the defense and aerospace sector, with recent expansion through acquisition of Seemann Composites and Materials Sciences. The company finances its operations through credit agreements that have been amended to increase borrowing capacity and reduce interest rates. Financial disclosures indicate positive net income and a solid liquidity position as of the end of 2025. Public news coverage focuses on the company's stock performance, analyst recommendations, and ETF inflows, reflecting market interest and activity.

Generation Income Properties, Inc. is a real estate company listed on Nasdaq under the ticker GIPR. The company owns and manages commercial real estate assets, including office and retail properties. In 2025, it completed sales of properties in Maitland, Florida and Grand Junction, Colorado, using proceeds to reduce mortgage debt. The company reported revenue of approximately $9.74 million and a net loss of $10.34 million for the fiscal year ended December 31, 2025. Cash and cash equivalents stood at about $6.16 million at year-end. The company is engaged in managing its Nasdaq listing compliance and has recently undergone leadership changes and strategic reviews.

AZUL SA operates as a major Brazilian airline with a broad domestic and international route network. The company focuses on providing frequent, affordable air service using a modern fleet, supplemented by ancillary businesses such as loyalty programs, cargo, and travel packages. The airline has undergone significant restructuring, including a Chapter 11 reorganization completed in late 2025, which reshaped its capital structure and fleet profile. AZUL's business model emphasizes network connectivity within Brazil and select international destinations, leveraging partnerships such as with United Airlines. The company manages operational costs through productivity improvements and fleet modernization, while navigating macroeconomic challenges and legal claims.

MDxHealth SA is a commercial-stage precision diagnostics company incorporated in Belgium in 2003. It focuses on non-invasive, clinically actionable, and cost-effective molecular diagnostic solutions for urologic diseases, primarily prostate cancer and urinary tract infections. The company’s core product portfolio includes Confirm mdx, GPS mdx, and Exo mdx tests, which provide personalized genomic insights to guide prostate cancer screening, diagnosis, and treatment decisions. The Exo mdx test, acquired in 2025, is a non-invasive urine test with a 91% negative predictive value for clinically significant prostate cancer, helping to reduce unnecessary biopsies. Confirm mdx and GPS mdx tests further aid in biopsy accuracy and risk stratification for treatment planning. The company also offers Resolve mdx, a rapid urinary tract infection test delivering patient-specific antibiotic recommendations. MDxHealth’s tests are recognized in major clinical guidelines such as NCCN and reimbursed by Medicare and commercial payors. The company operates CAP accredited and CLIA certified laboratories and maintains a direct sales force in the United States, targeting urology-focused networks. It continues to develop new tests, including Monitor mdx for active surveillance of prostate cancer. MDxHealth’s shares trade on Nasdaq under the ticker MDXH following delisting from Euronext Brussels in 2023.

Banzai International, Inc. operates as a Software as a Service (SaaS) company in the marketing technology (MarTech) sector, offering a comprehensive platform of AI-powered marketing tools designed to improve efficiency and impact for its customers. The company supports over 150,000 customers worldwide, including major enterprises such as Amazon and Salesforce. Its product suite includes solutions for video creation (OpenReel, CreateStudio), video hosting and marketing (Vidello), webinar hosting (Demio), webinar attendance boosting (Boost), targeted outreach (Reach), and AI-driven newsletters (Curate). Banzai's business model primarily relies on recurring subscription licenses with contract terms ranging from monthly to multi-year. The company pursues growth through organic customer acquisition, product development, cross-selling, and strategic acquisitions, including recent purchases of OpenReel, Vidello, and Superblocks. Banzai employs a hybrid go-to-market approach combining self-service and direct sales channels. The company is publicly traded on the Nasdaq Capital Market under the ticker BNZI.

TurnOnGreen, Inc. is a technology company specializing in premium custom power products and electric vehicle (EV) electrification infrastructure solutions. It operates through two wholly owned subsidiaries: Digital Power Corporation (DPC), which focuses on designing and manufacturing high-grade power conversion and power system solutions for diverse sectors such as e-Mobility, medical, military, telecommunications, and industrial markets; and TOG Technologies Inc. (TOGT), which markets scalable EV charging products and comprehensive charging management software and network services. The company leverages proprietary core power technologies, including integrated circuit implementations, to deliver cost-effective, high-efficiency, and high-density power solutions tailored to customer needs. TurnOnGreen aims to be the supplier of choice in markets requiring custom design, superior product quality, rapid time to market, and competitive pricing. The company serves mission-critical applications and has diversified its customer base across commercial, defense, and public sectors.

REGO Payment Architectures, Inc. is a Delaware-based FinTech company offering the Mazoola® digital wallet platform, targeting families with minors under 13 years old. The platform enables secure, compliant mobile payments and financial education under parental oversight. REGO's business model focuses on white label licensing, partnerships with financial institutions, and revenue sharing. The company emphasizes compliance with privacy laws such as COPPA, GDPR, and state-level regulations, and holds four US patents. It aims to serve the growing digital-native Gen Z and Gen Alpha demographics, as well as aging parents needing financial management tools. REGO faces a competitive payments industry landscape but differentiates through its family-centric, privacy-compliant approach. As of the end of 2025, the company had limited revenue and significant net losses, with a small employee base and outsourced development and marketing functions [S1][N1].

Skinvisible, Inc. operates through its subsidiary Skinvisible Pharmaceuticals Inc. as a pharmaceutical research and development company focused on its patented polymer delivery system, Invisicare®. This technology enhances topical delivery of active ingredients by extending their duration on the skin and improving efficacy while reducing irritation. The company has developed over forty topical skin products using Invisicare and targets large global markets in skincare, dermatology, over-the-counter products, and is exploring applications in obesity and other medical areas. Skinvisible's business model centers on out-licensing its patented products to established manufacturers and marketers worldwide, generating revenue from upfront fees and royalties. The company also provides co-development services and life cycle management by reformulating products coming off patent. Key license agreements include one with Quoin Pharmaceuticals for the development and commercialization of QRX003, a product in late-stage clinical trials for Netherton Syndrome, and another with Ovation Science for hand sanitizer and cannabinoid-based topical products targeting obesity and metabolic health. Skinvisible has filed provisional patents for transdermal delivery compositions for obesity drugs and glucose-controlling agents. Financially, the company reported minimal revenue and a net loss for the year ended December 31, 2025, with liquidity challenges and an accumulated deficit. The company is dependent on licensing revenue, regulatory approvals, and raising additional capital to continue operations.

Israel Acquisitions Corp is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in 2021. The company’s purpose is to complete a business combination with one or more target businesses. As of the end of 2025, the company had not commenced operations or completed a business combination. The company’s financial position includes cash and marketable securities held in a trust account, related party promissory notes, and accrued expenses. The company’s securities were delisted from Nasdaq in December 2025 due to failure to maintain minimum market value and now trade on the Pink Limited Market. The company is classified as an emerging growth company and faces typical risks associated with blank check companies, including uncertainty about completing a business combination and obtaining additional financing.

374Water Inc. develops AirSCWO technology designed to treat hazardous wastes, including PFAS-contaminated materials, through supercritical water oxidation processes. The company is in the early stages of commercializing this technology, having sold one system to date. Its business model relies heavily on government contracts and partnerships to deploy its technology in environmental remediation projects. The company faces challenges typical of early-stage technology firms, including limited operating history, ongoing net losses, and the need to scale production and sales. Management turnover and identified material weaknesses in financial controls add complexity to execution. The company has demonstrated its technology's effectiveness in Department of Defense projects and has formed strategic partnerships to advance deployment. Liquidity metrics as of the end of 2025 show the company maintains sufficient current assets relative to liabilities but continues to operate at a loss.

Cal Redwood Acquisition Corp. is a Cayman Islands exempted blank check company incorporated in January 2025. Its business purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more target businesses. The company intends to focus on technology, media, and telecommunications (TMT) sectors and industries undergoing technology disruption. It completed its initial public offering in May 2025, raising gross proceeds of $230 million plus $6.6 million from a private placement, with proceeds held in a trust account invested primarily in U.S. Treasury Bills. The company has not generated operating revenues and does not expect to do so until after consummation of its initial business combination. It announced a definitive business combination agreement with Carvix, Inc. in March 2026, with Thunder Rock Capital serving as exclusive financial advisor.

NEXGEL, INC. is a Delaware-incorporated company specializing in the manufacture of high water content, electron beam cross-linked aqueous polymer hydrogels used in wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company operates primarily as a contract manufacturer supplying gels to third parties, while also marketing its own branded consumer products and offering custom and white label hydrogel products. Its manufacturing facility in Pennsylvania operates at 15-20% capacity with significant room for expansion. The company is also developing medical devices such as NEXDrape and NEXDerm, focusing on licensing and partnerships for commercialization. NEXGEL faces competition from large established healthcare and consumer product companies and relies on a limited number of raw material suppliers. Sales are made on a purchase order basis without long-term contracts, leading to potential variability in revenue. The company reported a net loss in 2025 and has material weaknesses in financial controls. Recent strategic moves include a licensing and acquisition agreement with Celularity and leadership changes [S1][N3][N1].

Cartesian Growth Corp II is a Special Purpose Acquisition Company (SPAC) incorporated in the Cayman Islands in October 2021. Its purpose is to complete a business combination with one or more target companies, focusing on high-growth businesses with transnational operations. The company raised gross proceeds of $230 million in its May 2022 IPO, with additional funds from private placement warrants and sponsor loans. The company has not yet completed a business combination and has not generated operating revenues. Its securities were delisted from Nasdaq in May 2025 due to failure to complete a business combination within the required timeframe and now trade on the OTC Pink market. The company has extended the deadline to complete a business combination multiple times, with the current deadline set for August 5, 2026. It holds funds in a trust account to be used for the business combination or shareholder redemptions if no combination occurs. The company incurs operating costs related to public company compliance and due diligence activities. Liquidity constraints and the approaching deadline raise substantial doubt about the company's ability to continue as a going concern.

Streamex Corp. is a technology company that expanded its business in 2025 through the acquisition of Streamex Exchange Corporation, shifting from a medical device focus to a diversified platform centered on tokenized finance and real-world asset digitization. The company operates a blockchain-based infrastructure enabling issuance and trading of digital tokens backed by physical commodities, starting with gold. The legacy PURE EP™ Platform for cardiac electrophysiology remains part of the business but with limited recent commercial activity. As of the end of 2025, the tokenization platform was in development with no significant revenue, and the company reported substantial net losses primarily due to non-cash accounting charges and increased stock-based compensation. Streamex has strengthened its liquidity through public offerings and asset sales and manages its operations as a single reportable segment. The company also holds majority interests in subsidiaries with dormant or paused operations, evaluating strategic alternatives for these entities.

Aptose Biosciences Inc. is a science-driven clinical-stage biotechnology company developing precision medicines targeting unmet needs in oncology, with an initial focus on hematologic malignancies such as AML and hr-MDS. The company’s lead clinical candidate, tuspetinib, is an oral kinase inhibitor designed to target key kinases involved in tumor proliferation and resistance mechanisms while avoiding toxicities common to other kinase inhibitors. Tuspetinib is being developed primarily as a frontline combination therapy with venetoclax and azacitidine, investigated in the Phase 1/2 TUSCANY trial. Clinical data have shown promising safety and efficacy, including high complete remission rates and minimal residual disease negativity across diverse mutational subtypes. Aptose has a licensing agreement with Hanmi Pharmaceutical granting exclusive worldwide rights to tuspetinib and has entered into a definitive arrangement agreement for acquisition by Hanmi, with shareholder approval obtained in March 2026. The company’s financial position as of December 31, 2025, reflects ongoing operating losses and liquidity challenges, with reliance on financing from Hanmi and equity issuances to support clinical development and operations.

New Concept Energy, Inc. is a Nevada-based company with a history dating back to 1982 through predecessor entities. Its current operations focus on real estate leasing and advisory services for oil and gas operations. The company owns approximately 190 acres in Parkersburg, West Virginia, with four structures totaling about 53,000 square feet. The main industrial/office building has about 16,000 square feet leased, generating rental income. In 2020, the company sold its oil and gas wells and mineral leases but continues to provide management and advisory services under a consulting agreement that entitles it to 10% of the revenue from these wells. The company employs two people directly and outsources other work. It maintains property and liability insurance and has no long-term debt. Financially, the company reported $155,000 in revenue and a net loss of $46,000 for the year ended December 31, 2025, with strong liquidity ratios. The company’s stock trades on the NYSE American under the ticker GBR, with no dividends paid in recent years.

Netskope Inc is a technology company specializing in cybersecurity solutions. The company went public in September 2025, restructuring its share classes as part of the IPO. It generates revenue primarily through its cybersecurity products and services, though detailed product segmentation is not disclosed. Netskope maintains a strong liquidity position with over $1.1 billion in combined cash, cash equivalents, and short-term investments as of January 31, 2026. The company reports losses at the net income level, reflecting ongoing investments in growth and operations.

Liminatus Pharma, Inc. is a Nasdaq-listed emerging growth company with limited publicly disclosed information about its core business operations or industry classification. The company reported significant net losses and liquidity constraints as of the end of 2025. It has been subject to Nasdaq notifications for non-compliance with listing standards related to market value and bid price, with ongoing efforts to regain compliance. Recent corporate activities include capital raising through a public offering of shares and warrants and a strategic review of treasury management involving regulated digital assets.

New Providence Acquisition Corp. III is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in December 2024. Its business model is to raise capital through an IPO and then identify and complete a business combination with a target company, potentially in any industry. The company completed its IPO in April 2025, issuing over 30 million units and raising over $300 million, which are held in a trust account. It has no operating revenues to date and does not expect to generate revenues until after completing its initial business combination. The company is currently pursuing a business combination with Abra, including a merger agreement signed in March 2026. The management team has prior SPAC experience and a network to source acquisition targets. The company must complete its business combination by April 2027 or liquidate and return funds to shareholders. It may seek additional financing to complete the combination, which could affect shareholder dilution and capital structure.

Reliability Inc, headquartered in Maryland, operates primarily through its wholly owned subsidiary, The Maslow Media Group, Inc., offering workforce solutions including Employer of Record (EOR) services, staffing solutions, managed services, and video production services. The company serves a diverse client base across media, financial services, healthcare, telecommunications, pharmaceuticals, energy, and education sectors, both domestically and internationally. Maslow has expanded from media production management into broader workforce management, including IT, creative, marketing, and administrative staffing. The company’s EOR services manage employee lifecycle and compliance risks, while staffing solutions cover temporary, contract, direct hire, and managed services. Video production services encompass pre-production through live broadcast and studio management. The company’s revenue declined in 2025 due to reduced activity from major clients and client attrition, with a net loss reported. Liquidity is supported by cash, receivables financing, and factoring arrangements. The company resolved a significant arbitration dispute with the Vivos Group in 2026, leading to share transfers to the company. The staffing industry is cyclical and influenced by macroeconomic and regulatory factors, with growing demand for flexible workforce models and outsourced compliance solutions.

Faraday Future Intelligent Electric Inc. operates in the electric vehicle and robotics sectors, developing advanced EAI (Electric Autonomous Intelligence) vehicles and robotics products. The company has recently launched multiple robot products across three categories and is actively engaging partners through recruitment events. It has completed U.S. regulatory certification for its first EAI Robotics product, which is poised to begin sales. Faraday Future is expanding its presence internationally, showcasing its technology in markets such as the Middle East. The company is navigating financial challenges, including significant net losses and liquidity constraints, and is currently under Nasdaq's minimum bid price compliance requirements.

Independence Power Holdings, Inc. is engaged in the deployment and operational management of a fleet of 101 modified containerized Battery Energy Storage System (BESS) units acquired from GridCore. The company operates through wholly owned subsidiaries including DBD Express and Kyma Batteries, providing asset management services for the BESS fleet under commercial agreements. It utilizes an embedded operating system and software platform to manage operations at centralized battery rental yards and field sites. The company also maintains administrative services agreements with related parties to support staffing, payroll, accounting, and other administrative functions. Additionally, it leases property in Wisconsin for warehouse, research and development, and office use. The company reported fiscal year 2025 revenue of approximately $97.2 million and maintains a strong liquidity position with a current ratio of 17.38 as of December 31, 2025. TriUnity Business Services Limited, a Nevada corporation and subsidiary, provides business administration services such as accounting, human resources management, payroll, and head-hunting primarily in Malaysia, with reported revenues of $333 and a net loss of $10,206 for the three months ended October 31, 2025.

Digi Power X Inc. develops and operates data center facilities and provides enterprise colocation and AI/GPU infrastructure services, integrating energy production with digital currency mining. The company owns a 60 MW gas-fired power plant operating as a peaker plant and participates in mining pools to generate digital currency revenues. It emphasizes sustainable energy use, sourcing 89% of its electricity from zero-carbon generation and targeting full carbon neutrality by 2026. The company holds digital assets in a Gemini account and manages mining operations with remote and on-site monitoring. As of the latest report, Digi Power X employs 17 people and reported $34.2 million in revenue with a net loss of $28.4 million for the year ended December 31, 2025.

Patriot National Bancorp, Inc. is a bank holding company headquartered in Connecticut, with its primary operating asset being Patriot Bank, N.A. The Bank operates eight branches in Connecticut and New York and a banking office in Beverly Hills, California. The company completed a substantial transformation in 2025 involving capital structure changes, management reconstitution, and strategic repositioning. The Bank operates under a Formal Agreement with the OCC requiring corrective actions in capital, governance, risk management, and compliance. Its business model focuses on relationship-driven banking and specialized financial services targeting entrepreneurs, investors, digital payments clients, and underbanked but creditworthy customers. Lending activities emphasize commercial real estate, high-net-worth credit facilities, and asset-backed financing. The Bank offers traditional deposit products and treasury management services, with institutional banking and digital payments as important sources of deposits and fee income. The company reported a net loss for 2025 and has increased liquidity and capital through private placements and registered offerings. The Bank faces regulatory scrutiny and operates in a competitive financial services environment.

CannaPharmaRX, Inc. is a cannabis production company with operations centered at its Cremona, Alberta facility. The company currently operates six of ten growing rooms and plans to open the remaining rooms within one to two years. It is actively expanding its presence in European markets, particularly Germany and Israel, and aims to obtain EU-GMP certification to facilitate direct shipments to EU countries. The company is managing significant debt obligations through negotiated payment schedules while focusing on growing its operations and product delivery.

Mainz Biomed N.V. develops and markets genetic diagnostic tests for early cancer detection, with a focus on colorectal and pancreatic cancers. The company was incorporated in 2021 and is headquartered in Mainz, Germany. It historically marketed ColoAlert, a CE-IVD certified colorectal cancer screening test in Europe, combining fecal immunochemical testing with PCR-based genetic marker analysis. Clinical studies demonstrated high sensitivity and specificity for colorectal cancer and advanced adenomas. In 2025, Mainz Biomed acquired exclusive rights to novel mRNA biomarkers and AI algorithms for non-invasive pancreatic cancer detection via blood tests and is developing PancAlert, a stool-based pancreatic cancer screening test. In early 2026, the company decided to discontinue ColoAlert and next-generation colorectal cancer product development, selling related intellectual property, and is shifting strategic focus toward post-quantum cybersecurity while continuing pancreatic cancer test development. The company reported a net loss of $16.2 million for fiscal 2025 and has implemented cost reductions including significant personnel cuts.

Vynleads, Inc. operates as a wellness technology company targeting metabolic health and chronic lifestyle-influenced conditions. Its primary product is the Done With Diabetes app, an eight-week structured program designed to support adults with type 2 diabetes and related conditions through lifestyle education, habit formation, and AI-enabled coaching. The platform integrates a proprietary personalization engine and an emerging agentic AI architecture to deliver daily missions, meal guidance, community features, and ongoing maintenance support. The company is shifting from one-time digital wellness products to a recurring subscription model priced at $29 per month, aiming to scale direct-to-consumer subscriptions and enterprise partnerships with employers, health plans, and payers. The platform is cloud-based and relies on third-party technology providers, with a small internal team. Vynleads faces competition from established digital health and wellness vendors and operates under various regulatory frameworks related to consumer protection, privacy, and AI use.

Smart Powerr Corp. is a Nevada-incorporated holding company conducting most of its business through subsidiaries in China. Historically a pioneer in waste energy recycling, the company uses a Build-Operate-Transfer model to provide energy saving and recovery facilities to energy-intensive industries. Its projects capture industrial waste energy to generate electricity, reducing energy costs and emissions for customers. The company is transitioning towards becoming an energy storage integrated solution provider, targeting new markets such as industrial complexes, renewable energy stations, remote islands, and smart energy cities. Operations are conducted through multiple wholly-owned subsidiaries in China. The company reported modest revenue and a net loss for the fiscal year ending 2025, with strong liquidity. It has not paid dividends and retains earnings for business operations and expansion. The company faces legal and operational risks related to PRC regulations and operates in a competitive market with risks from manufacturing dependencies and project execution delays [S1].

enCore Energy Corp. is a uranium extraction company incorporated in 2009, operating primarily in the United States. The company focuses on domestic uranium production using proven in-situ recovery (ISR) technology, which is environmentally responsible and cost-efficient. enCore owns and operates three of the ten licensed ISR Central Processing Plants (CPPs) in the U.S., all located in Texas, including the Rosita and Alta Mesa projects where uranium extraction commenced in 2023 and 2024 respectively. The company holds significant mineral resources compliant with SEC S-K 1300 standards across Texas, South Dakota, Wyoming, and New Mexico. enCore's business model includes uranium extraction, processing, and sales under multi-year contracts with major U.S. utilities. The company has a joint venture with Boss Energy Limited for the Alta Mesa Project and continues to optimize operations, manage costs, and rationalize its asset base. enCore is subject to competitive pressures from larger uranium producers and geopolitical risks affecting supply chains and market conditions. The company employs a workforce of over 250 individuals, including full-time employees and contractors, and emphasizes talent development and retention.

Brainstorm Cell Therapeutics Inc. focuses on developing and commercializing autologous adult stem cell therapies for neurodegenerative diseases such as ALS, progressive multiple sclerosis, and Alzheimer's disease. Its proprietary NurOwn® technology involves harvesting a patient’s own bone marrow-derived mesenchymal stem cells, differentiating them into neurotrophic factor secreting cells, and administering them intrathecally. The company has conducted late-stage clinical trials for NurOwn® in ALS and holds Fast Track and Orphan Drug designations from the FDA. Manufacturing is conducted in Israel under GMP standards. The company’s stock trades on the OTCQB Venture Market following delisting from Nasdaq due to equity requirements. Brainstorm has not yet generated revenues and continues to incur operating losses, with liquidity constraints noted in recent financial disclosures.

20/20 Biolabs, Inc. is a U.S.-based diagnostics company specializing in AI-powered, laboratory-based blood tests aimed at early detection and prevention of cancers and chronic diseases. Its primary products are the OneTest for Cancer, a multi-cancer early detection test using protein tumor markers combined with AI algorithms, and OneTest for Longevity, which measures inflammatory biomarkers related to chronic disease risk. The company operates a CAP-accredited, CLIA-licensed laboratory in Gaithersburg, Maryland, and also offers a Clinical Laboratory Innovation Accelerator (CLIAx) service for overseas diagnostic startups. Legacy products include BioCheck, a field test kit for bioterror agent screening. The company has reagent supply agreements with Roche and Abbott and relies on a network of retail blood draw providers. Revenue is primarily derived from OneTest for Cancer, with smaller contributions from BioCheck and CLIAx. The company faces competition from other MCED providers, including ctDNA-based tests, and emphasizes affordability and early-stage detection sensitivity as key differentiators.

VASO Corp is a diversified healthcare company operating through three main segments: IT services via VasoTechnology, professional sales services through VasoHealthcare, and proprietary medical equipment manufacturing and sales via VasoMedical. The IT segment focuses on managed network infrastructure, transport, and security services, having divested its healthcare IT business in November 2025. The professional sales service segment acts as the exclusive sales representative for GE HealthCare Technologies' diagnostic imaging and ultrasound equipment in specific U.S. markets, supported by a large sales force and proprietary sales management tools. The equipment segment develops and markets cardiovascular diagnostic and therapeutic devices and software, including EECP therapy systems, ambulatory monitoring devices, and cloud-based analysis software, selling directly in the U.S. and China and through distributors internationally. The company reported $89.1 million in revenue and $1.57 million net income for fiscal 2025, with a strong liquidity position. The GE HealthCare sales agreement is critical to the company's revenue and operating income. The company has a history of strategic divestitures and partnerships, including the sale of its healthcare IT unit and a management service agreement for EECP Global Corporation.

BluSky AI Inc. is a Nevada-based company specializing in AI compute infrastructure through modular data centers equipped with high-performance GPUs. The company targets the growing demand for AI and machine learning workloads by offering flexible, high-density computing solutions. BluSky AI relies on partnerships with modular data center providers and GPU manufacturers such as NVIDIA and AMD. The company integrates renewable energy sources into its operations, emphasizing sustainability. However, BluSky AI faces significant challenges including supply chain disruptions, competition from large hyperscale providers, limited access to powered land assets, and difficulties in talent acquisition. Financially, the company has incurred losses since inception, with liquidity constraints and substantial current liabilities exceeding current assets as of the end of 2025. Management has expressed concerns about the company's ability to continue as a going concern. The company’s stock trades on the OTC market and is classified as a penny stock, which may affect liquidity and investor access.

Spruce Power Holding Corporation is a U.S.-based company specializing in the ownership and operation of distributed solar energy assets, primarily residential home solar systems. It offers subscription-based services to homeowners under long-term contracts that generate recurring monthly payments. The company also sells solar renewable energy credits and provides portfolio management services through its Spruce Pro platform, servicing both its own and third-party solar assets. Spruce Power has grown through acquisitions, including several large portfolios acquired between 2022 and 2025, resulting in a diversified portfolio of approximately 84,000 home solar assets across 18 states. The company focuses on leveraging its platform to expand subscription-based distributed energy solutions, improve customer service, and increase shareholder value through predictable revenues and cash flows. It operates with in-house capabilities for billing, collections, customer support, and asset management. The company faces competition from vertically integrated solar companies, finance-focused entities, and regulated utilities. It is subject to various regulatory requirements and government incentives related to solar energy. Financially, Spruce Power reported net losses and has significant debt obligations, with liquidity and refinancing risks noted in its latest filings.